Literature DB >> 31153863

Anxiolytic- and anxiogenic-like effects of Montanoa tomentosa (Asteraceae): Dependence on the endocrine condition.

Erika Estrada-Camarena1, Isabel Sollozo-Dupont2, Dannia Islas-Preciado3, María Eva González-Trujano4, Miguel Carro-Juárez5, Carolina López-Rubalcava6.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Montanoa tomentosa Cerv. (MT) is a native plant from Mexico used in traditional medicine as a remedy for reproductive impairments and relaxing effects. In previous studies, it has been shown that the endocrine state could modify the antianxiety-like actions of anxiolytic compounds. Although women are the primary user of MT, no studies have evaluated the potential impact of the endocrine milieu on its anti-anxiety actions. AIMS OF THE STUDY: Ascertain the antianxiety effects of M. tomentosa in rats with different hormonal conditions, and to analyze the participation of the GABAA receptor in ovariectomized rats treated with MT.
MATERIALS AND METHODS: The animal model of anxiety used was the elevated plus-maze (EPM). Rats' endocrine conditions were: a) Low hormone levels (rats in diestrus I and II phases); b) High hormone levels (proestrus/estrus phases); c) No hormones (ovariectomized rats); and d) Rats under progesterone withdrawal (PW). To evaluate the participation of the GABAA receptor in the anxiolytic-like action of MT the antagonist picrotoxin was used.
RESULTS: Results showed that MT induced dose-dependent anxiolytic-like actions in rats with low hormone level conditions. Also, MT reduced anxiety-like behavior in female rats under PW, in contrast to diazepam which was ineffective. MT's anxiolytic-like effect was blocked by picrotoxin, suggesting the participation of the GABAA receptor complex. However, increased anxiety-like behavior was observed in rats with a high hormone level condition and low doses of MT.
CONCLUSIONS: Beneficial anxiolytic-like actions of MT are observed under low hormone conditions, particularly in the PW challenge (a condition that can be related to a premenstrual period). Furthermore, the participation of the GABAA receptor is evidenced. However, hormonal variations could induce the opposite effects, hence women should be cautious.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiolytic-like effect; Elevated plus-maze; Estrous cycle; GABA(A) receptor; Montanoa tomentosa; Progesterone withdrawal

Year:  2019        PMID: 31153863     DOI: 10.1016/j.jep.2019.112006

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  4 in total

1.  Antibacterial Activity and Reversal of Multidrug Resistance of Tumor Cells by Essential Oils from Fresh Leaves, Flowers, and Stems of Montanoa quadrangularis Schultz Bipontinus (Asteraceae) Collected in Mérida-Venezuela.

Authors:  Janne Rojas; Gautier Mark-Arthur Ndong Ntoutoume; Patrick Martin; Marielba Morillo
Journal:  Biomolecules       Date:  2021-04-19

2.  Anxiety-like Behavior and GABAAR/BDZ Binding Site Response to Progesterone Withdrawal in a Stress-Vulnerable Strain, the Wistar Kyoto Rats.

Authors:  Dannia Islas-Preciado; Gabriela Ugalde-Fuentes; Isabel Sollozo-Dupont; María Eva González Trujano; Nancy Cervantes-Anaya; Erika Estrada-Camarena; Carolina López-Rubalcava
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

3.  Under or Absent Reporting of Light Stimuli in Testing of Anxiety-Like Behaviors in Rodents: The Need for Standardization.

Authors:  Lorenz S Neuwirth; Michael T Verrengia; Zachary I Harikinish-Murrary; Jessica E Orens; Oscar E Lopez
Journal:  Front Mol Neurosci       Date:  2022-08-17       Impact factor: 6.261

4.  GABA A /Benzodiazepine Receptor Complex in the Dorsal Hippocampus Mediates the Effects of Chrysin on Anxiety-Like Behaviour in Female Rats.

Authors:  Juan Francisco Rodríguez-Landa; Fabiola Hernández-López; Lucía Martínez-Mota; Damiana Scuteri; Blandina Bernal-Morales; Eduardo Rivadeneyra-Domínguez
Journal:  Front Behav Neurosci       Date:  2022-01-05       Impact factor: 3.558

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.